CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 78 enrolled
Drug / intervention
11-point pain scale +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04341298
NCT04341298N/ACompleted
CompareCT.gov

Clinical Evaluation of Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches

Avulux, Inc.·interventional·Posted Apr 10, 2020·Updated Jan 9, 2023

In Brief

A clinical study evaluating 11-point pain scale, Headache diary, and 2 other interventions for Migraine. Completed, enrolled 78 participants across 3 sites.

Detailed Summary

The purpose of this research is to assess how well the Avulux® migraine lenses work in reducing the impact of migraine headaches as measured by improvement in an 11-point pain scale after two and four hours of device application, when compared to a control device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsImarc Research, Inc.

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 10, 2020
Enrollment StartApr 6, 2020
Primary CompletionAug 26, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.2 years ago

Interventions

11-point pain scaleother

Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.

Headache diaryother

Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.

Avulux®device

Avulux® device

Sham Avulux®device

Sham Avulux®